Your Messages Inbox
Your Article Summary
See Latest ArticlesAbbott Receives European Approval for Once-Daily Dosing of Kaletra Tablet
Abbott, 09/15/09
Abbott announced that it has received marketing authorization from the European Commission for once–daily dosing of the Kaletra tablet, the company’s leading HIV protease inhibitor, in adult patients new to HIV therapy. The Kaletra tablet is now approved for once–daily as well as twice–daily use in this patient population in combination with other antiretroviral agents, giving physicians another option when deciding on the most appropriate HIV dosing regimen.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Article Search
Sponsor